Kaplan–Meier estimates of the proportion of patients with an ongoing response over time. DOR in the overall population (A) and BTKi (B), number of prior therapy lines (C), and bendamustine (D) subgroups. In panel A, CR and CR/PR denote best responses achieved. Vertical dashed lines indicate 6- and 12-month landmarks.